Phaseline

Companies › Trellis Bioscience

Trellis Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRL1068 (calpurbatug)
Human monoclonal antibody targeting biofilm in prosthetic joint infections
–Phase 2Prosthetic Joint Infections of HipApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06621251TRL1068 (calpurbatug)Phase 2Prosthetic Joint Infections of HipInfectious diseaseApr 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zura Bio Amplexd Therapeutics Biothervax Sano Chemicals Hyundai Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.